Semaglutide's journey from peptide engineering to blockbuster drug shows how molecular modifications enabled once-weekly dosing, major weight loss, and cardiovascular benefits across landmark clinical trials.
~65% lost ≥15% body weightIn the STEP clinical trials for chronic weight management, nearly two-thirds of semaglutide-treated patients achieved at least 15% weight loss
What the researchers found
Semaglutide's development from concept to blockbuster therapy was driven by strategic molecular engineering — amino acid substitutions and a C18 fatty-diacid side chain that extended the peptide's half-life to approximately 160 hours, enabling once-weekly dosing. The SUSTAIN clinical program demonstrated significant HbA1c reductions and weight loss compared to other treatments, plus a 26% decrease in the relative risk of major adverse cardiovascular events (SUSTAIN-6). The STEP trials expanded semaglutide's use to chronic weight management, showing nearly two-thirds of patients achieved at least 15% body weight reduction.
Optimal weekly doses were established at 0.5 mg and 1.0 mg in phase II trials. Regulatory approvals from the FDA, EMA, and other agencies were obtained between 2017 and 2021.
Why it matters
Semaglutide has become one of the most consequential peptide drugs ever developed, transforming treatment for type 2 diabetes and obesity simultaneously. Its story demonstrates how deliberate peptide engineering can overcome the traditional limitations of peptide therapeutics — short half-life and poor oral bioavailability. With ongoing research into metabolic liver disease, cardiovascular events, and chronic kidney disease, semaglutide's therapeutic reach continues to expand.
The numbers in context
Half-life: ~160 hours · Weekly doses: 0.5 mg and 1.0 mg · 26% reduction in major cardiovascular events (SUSTAIN-6) · ~65% of patients lost ≥15% body weight (STEP) · Approved 2017–2021
How the study worked
This is a comprehensive narrative review analyzing preclinical datasets, phase I–III clinical trials, regulatory documents, and pharmacoepidemiological studies published between 2008 and 2025. The review covers the full translational pipeline from medicinal chemistry and animal studies through the pivotal SUSTAIN and STEP trial programs to post-marketing real-world surveillance.
Who was studied
Adults with type 2 diabetes and/or obesity (review of multiple trial populations)
What this study cannot tell us
As a narrative review, this paper synthesizes existing data rather than presenting new primary research. The review scope is limited to published literature through 2025 and may not capture the most recent real-world outcomes or ongoing trial results for newer indications like MASH and chronic kidney disease.
How to read the evidence
This review synthesizes data from the landmark SUSTAIN and STEP randomized controlled trial programs, which are among the largest and most rigorous in metabolic medicine. The evidence is strong due to the breadth of phase I–III data, cardiovascular outcomes trials, and post-marketing surveillance covered.
When this study was published
Published in 2025, this review covers evidence through 2025 and includes the most current data on semaglutide's approved uses and ongoing research directions.
The bigger picture
Semaglutide represents a watershed moment in peptide therapeutics. Its success has catalyzed an entire class of GLP-1 and dual-agonist drugs (like tirzepatide) and demonstrated that peptides — once considered too fragile for convenient dosing — can be engineered into best-in-class medicines. The drug's expansion into cardiovascular protection, weight management, and potentially liver and kidney disease illustrates how a well-designed peptide can address multiple facets of metabolic syndrome. Semaglutide's development story has become a template for modern peptide drug design.
Questions still open
- Will semaglutide prove effective for metabolic dysfunction-associated steatohepatitis (MASH) and chronic kidney disease in ongoing trials?
- What are the long-term effects of sustained GLP-1 receptor agonism over decades of use?
- How will oral formulations of semaglutide compare to injectable versions in real-world adherence and outcomes?
Common questions
How does semaglutide last a full week in the body when natural GLP-1 breaks down in minutes?
Does semaglutide only help with blood sugar, or does it have other health benefits?
Read the original research
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.
Medical sciences (Basel, Switzerland), 13(4)
Citation
Weiskirchen, Ralf; Lonardo, Amedeo. (2025). Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.. Medical sciences (Basel, Switzerland), 13(4). https://doi.org/10.3390/medsci13040265